A class action lawsuit has been filed against Replimune Group, Inc. and some of its officers for allegedly making false statements and failing to disclose critical information about FDA study design concerns and incomplete data submissions during October 2025 to April 2026. The lawsuit claims Replimune submitted early, limited patient data that likely caused FDA rejection of their Biologics License Application (BLA), misleading investors about the company's business prospects. Investors who bought Replimune securities during this period can join the lawsuit and have until October 5, 2026, to request lead plaintiff status. The law firm Bronstein, Gewirtz & Grossman, LLC is representing affected investors on a contingency fee basis.
Korn Ferry reported strong Q1 results with earnings per share of $1.43 and revenue of $756.5 million, both exceeding analyst expectations and marking continued growth. Despite this, the stock fell due to conservative guidance for the next quarter, wh...
SailPoint reported Q2 2026 earnings with revenue of $308.81 million, slightly below estimates but up 17% year-over-year. Adjusted EPS of $0.09 beat analyst expectations by 12.5%, reflecting improved profitability. The company showed strong subscripti...
The Cooper Companies is set to report its Q3 2026 earnings with analysts expecting earnings per share (EPS) of $1.12 and revenue of $1.10 billion, both showing growth from the previous year. Despite a recent 2.7% drop in stock price to $67.69, an ana...
Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...
Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...
